News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
264,262 Results
Type
Article (13712)
Company Profile (101)
Press Release (250449)
Section
Business (88014)
Career Advice (465)
Deals (15341)
Drug Delivery (66)
Drug Development (36580)
Employer Resources (49)
FDA (6283)
Job Trends (6193)
News (150157)
Policy (14022)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Pharm Country Standard (1)
Academia (438)
Adcomms (6)
Allergies (28)
Alliances (23205)
ALS (32)
Alzheimer's disease (377)
Antibody-drug conjugate (ADC) (33)
Approvals (6307)
Artificial intelligence (93)
Autoimmune disease (4)
Automation (3)
Bankruptcy (146)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (49)
Biotechnology (40)
Bladder cancer (17)
Brain cancer (13)
Breast cancer (70)
Cancer (521)
Cardiovascular disease (54)
Career advice (406)
Career pathing (10)
CAR-T (17)
Cell therapy (74)
Cervical cancer (4)
Clinical research (30766)
Collaboration (286)
Compensation (116)
Complete response letters (16)
COVID-19 (754)
CRISPR (18)
C-suite (99)
Cystic fibrosis (35)
Data (524)
Denatured (15)
Depression (9)
Diabetes (70)
Diagnostics (1310)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (50)
Drug pricing (61)
Drug shortages (11)
Duchenne muscular dystrophy (26)
Earnings (31877)
Editorial (11)
Employer branding (4)
Employer resources (43)
Events (37239)
Executive appointments (323)
FDA (6618)
Featured Employer (21)
Friedreich's ataxia (2)
Funding (179)
Gene editing (34)
Generative AI (8)
Gene therapy (90)
GLP-1 (324)
Government (1281)
Grass and pollen (2)
Guidances (14)
Healthcare (3556)
Huntington's disease (4)
IgA nephropathy (8)
Immunology and inflammation (24)
Indications (10)
Infectious disease (783)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (12)
Intellectual property (35)
Interviews (59)
IPO (5869)
IRA (28)
Job creations (2050)
Job search strategy (372)
Kidney cancer (6)
Labor market (7)
Layoffs (175)
Leadership (3)
Legal (3427)
Liver cancer (18)
Lung cancer (71)
Lymphoma (45)
Machine learning (1)
Management (16)
Manufacturing (127)
MASH (28)
Medical device (1272)
Medtech (1274)
Mergers & acquisitions (9621)
Metabolic disorders (222)
Multiple sclerosis (16)
NASH (14)
Neurodegenerative disease (19)
Neuropsychiatric disorders (5)
Neuroscience (529)
NextGen: Class of 2025 (1585)
Non-profit (593)
Northern California (621)
Now hiring (7)
Obesity (126)
Opinion (116)
Ovarian cancer (18)
Pain (44)
Pancreatic cancer (13)
Parkinson's disease (39)
Partnered (5)
Patents (91)
Patient recruitment (26)
Peanut (9)
People (28775)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8008)
Phase II (13015)
Phase III (11678)
Pipeline (307)
Podcasts (44)
Policy (54)
Postmarket research (1401)
Preclinical (3191)
Press Release (25)
Prostate cancer (40)
Psychedelics (8)
Radiopharmaceuticals (118)
Rare diseases (147)
Real estate (2632)
Recruiting (17)
Regulatory (10022)
Reports (13)
Research institute (563)
Resumes & cover letters (55)
RSV (6)
Schizophrenia (31)
Series A (32)
Series B (11)
Service/supplier (3)
Sickle cell disease (30)
Southern California (622)
Special edition (5)
Sponsored (6)
Startups (1626)
State (2)
Stomach cancer (3)
Supply chain (27)
The Weekly (28)
United States (6220)
Vaccines (136)
Venture capitalists (13)
Webinars (10)
Weight loss (89)
Women's health (8)
Worklife (3)
Date
Today (59)
Last 7 days (285)
Last 30 days (1099)
Last 365 days (12359)
2025 (2117)
2024 (12500)
2023 (14246)
2022 (19556)
2021 (20068)
2020 (19032)
2019 (14885)
2018 (11713)
2017 (13889)
2016 (13132)
2015 (15474)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (46)
Arkansas (3)
Asia (20022)
Australia (2595)
California (1491)
Canada (813)
China (195)
Colorado (61)
Connecticut (62)
Delaware (49)
Europe (39217)
Florida (267)
Georgia (34)
Idaho (9)
Illinois (166)
India (11)
Indiana (120)
Iowa (1)
Japan (76)
Kansas (54)
Kentucky (12)
Maine (2)
Maryland (227)
Massachusetts (1274)
Michigan (27)
Minnesota (82)
Missouri (21)
Montana (8)
Nebraska (6)
Nevada (7)
New Hampshire (6)
New Jersey (639)
New Mexico (7)
New York (423)
North Carolina (353)
North Dakota (2)
Northern California (621)
Ohio (43)
Oklahoma (4)
Oregon (16)
Pennsylvania (374)
Puerto Rico (5)
Rhode Island (5)
South America (500)
South Carolina (2)
Southern California (622)
Tennessee (29)
Texas (197)
Utah (32)
Virginia (65)
Washington D.C. (29)
Washington State (101)
Wisconsin (12)
264,262 Results for "micurx pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
MicuRx Pharmaceutical: Contezolid Global Phase III Clinical Trial Safety and Efficacy Evaluation Endorsed by Data Monitoring Committee, Promising Prospects for Diabetic Foot Infection Treatment
February 25, 2025
·
4 min read
MicuRx To Present New Data At 7th World Bronchiectasis Conference
Shanghai MicuRx Pharmaceutical Co., Ltd. announced 3 new studies will be presented at the 7th World Bronchiectasis Conference, taking place from July 4 - 6, 2024 in Dundee, Scotland.
June 19, 2024
·
2 min read
Press Releases
FDA Grants Orphan Drug Designation to MicuRx’s MRX-5 for NTM Infections
January 2, 2025
·
2 min read
News
MicuRx Pharmaceuticals Showcases the Pipeline Status of MRX-5 and MRX-8 at BIO Investor Forum
October 18, 2024
·
2 min read
Drug Development
MicuRx: Successful Completion of Phase I Clinical Trial for Self-Developed MRX-8 Antibacterial Drug in China
Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. successfully completed the Phase I clinical trial of its self-developed new injectable polymyxin antibacterial drug MRX-8 in China, achieving the expected goals.
June 6, 2024
·
5 min read
Press Releases
MicuRx: Successfully Completes Phase III Clinical Trial of MRX-4 for Injection in China
December 2, 2024
·
3 min read
Press Releases
MicuRx Pharmaceuticals Announces Promising Results from MRX-5 Study for Treating Mycobacterium abscessus Infections
October 8, 2024
·
2 min read
News
MicuRx Announces the Successful Completion of Phase 1 Clinical Trial of MRX-5 in Australia
October 25, 2024
·
3 min read
Biotech Bay
MicuRx announces poster presentation and participation in ID Week 2023 Conference
MicuRx Pharmaceuticals, Inc. announces that a poster on our preclinical product, MRX-6038, will be presented at ID Week entitled “In vitro Potency of a Leucyl-tRNA Synthetase Inhibitor, MRX-6038, Against Mycobacterium tuberculosis, Mycobacterium avium, and Mycobacterium abscessus.”
October 11, 2023
·
2 min read
Press Releases
MicuRx Presents Innovative Antibiotic Research Results at the 7th World Bronchiectasis Conference
July 18, 2024
·
5 min read
1 of 26,427
Next
